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Medication overuse headache (MOH) is common with a prevalence 
ranging from 0.5% to 7.2% reported in population studies, and is es‐
timated to cause about half of chronic headache cases (Aaseth et al., 
2008; Westergaard, Glumer, Hansen, & Jensen, 2014). MOH, a condi‐
tion that largely could be avoided, is disabling and costly to both indi‐
viduals and society (GBD, 2015; Neurological Disorders Collaborator 
Group, 2017; Linde et al., 2012). Since the presence of migraine or 
another primary headache disorder is a necessary precursor for the 
development of MOH, this add‐on headache is an important focus for 
prevention and reduction of headache‐related disability (Munksgaard 
& Jensen, 2014). Patient education and preventive treatment are im‐
portant steps in the management of these patients (Diener, Holle, 
Solbach, & Gaul, 2016). MOH is a common group of headache patients 
among those referred to specialist for second opinion from general 
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Abstract
Objective: To test the hypothesis that the effect of video consultations is noninferior 
to traditional consultations in managing patients with overuse headache (MOH).
Materials and Methods: Patients were recruited from referrals to a neurological 
clinic. In a randomized controlled trial (RCT), headache burden measured by head‐
ache impact test (HIT‐6) and frequency of headache days <15 per month and visual 
analogue pain scale (VAS) at baseline, 3 months and 1 year were compared between 
groups consulted by video‐ (n = 51) and traditional consultations (n = 51) in a post hoc 
analysis.
Results: The overall response rate was 74.5%. HIT‐6 changed from 66.3 (SD = 4.7) 
to 60.0 (SD = 9.1) from baseline to 12 months in participants randomized to video 
consultations and from 65.8 (SD = 3.7) to 58.4 (SD = 8.3) in the group consulted tradi‐
tionally	(95%	CI	−2.3	to	6.5,	p = 0.44). Frequency of headache days <15 per month at 
1‐year follow‐up were 9 (23.1%) respectively 10 (27.0%), p = 0.60. In the video group, 
VAS improved by 2.3 points compared to 2.4 in the traditional group from baseline to 
12	months	(95%	CI	−1.2	to	1.2,	p = 0.76). Analyses of repeated measurements com‐
paring HIT‐6 and VAS over two points of time in the two groups were insignificant.
Conclusion: The effect of video consultations is noninferior to traditional consulta‐
tions in managing MOH patients. Using video may be a good alternative in consulting 
patients with MOH.
K E Y W O R D S
headache, health service, management, medication overuse headache, MOH, RCT, 
telemedicine
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practitioners (Muller, Alstadhaug, & Bekkelund, 2016a). It is, however, 
important to be aware that consequences of painkiller use in head‐
ache patients may be unrecognized (Bekkelund & Salvesen, 2002). The 
costs per visit for rural headache patients visiting a headache specialist 
in North Norway were estimated to €249 (travel cost) and €234 (loss 
of income; Muller, Alstadhaug, & Bekkelund, 2016b). Furthermore, ac‐
ceptability and feasibility using video in consulting nonacute headache 
patient were favourable (Muller et al., 2016b).
Access to care and patient's preferences are important el‐
ements to consider when organizing an optimal service for the 
patients. Access variability for headache sufferers referred to a 
specialist is a recognized problem (Tassorelli, Farm, et al., 2014). 
A cross‐sectional study showed that MOH patients (n = 65) pre‐
ferred information to be given personally (Munksgaard et al., 2011). 
They also preferred consultations by telephone to e‐mail or other 
sources of information, but video consultations were not evalu‐
ated (Munksgaard et al., 2011). Lack of well‐documented treat‐
ment standards and best practice strategies add to the complexity 
in the management of the disorder (de Goffau, Klaver, Willemsen, 
Bindels, & Verhagen, 2017). In this study, we investigated whether 
use of video consultations is effective in the treatment of patients 
with MOH referred for second opinion to a neurological outpa‐
tient department. The primary hypothesis was that the treatment 
effect of video consultations is noninferior to traditional consulta‐
tions in managing MOH patients.
2  | MATERIAL S AND METHODS
2.1 | Study design and patients
The present study is secondary research based on a noninferiority 
randomized controlled trial (RCT) comparing treatment outcomes 
between groups of headache patients referred to Neurologist con‐
sulted by using video and in the traditional manner. All consultations 
were organized and completed at the Department of Neurology in 
Tromsø University Hospital, Norway, which is the only neurologi‐
cal specialist center in the region (Northern part of Norway includ‐
ing Svalbard). Altogether, the hospital served 268,511 inhabitants 
(December 2014) living in an area of 140,541 km2 according to 
Norway Statistics. In the study period (30 September 2012 until 30 
March 2015), we consecutively screened 557 and enrolled 402 in 
the study. Of them, n = 102 had a diagnosis of MOH (Figure 1).
A study nurse received the patients at the entrance, controlled the 
self‐administered prefilled questionnaires, Headache Impact Test‐6 
(HIT‐6, Yang, Rendas‐Baum, Varon, & Kosinski, 2011), a horizontal vi‐
sual analogue scale (VAS) ranging from 0 to 10; 0 = no pain, 10 = worst 
possible pain (Lundqvist, Benth, Grande, Aaseth, & Russell, 2009), 
and consent forms and then called the external Research Department 
at the University Hospital for block randomization. A computerized 
randomization using an Rnd function in Microsoft Access was per‐
formed before patients were guided either to a patient examination 
room at the department (traditional group) or to a videoconference 
room located next to it (video group) out of examiners view. The 
videoconference room had a Cisco C40 integrator package installed 
providing a direct and encrypted two‐way video and audio commu‐
nication between neurologist and patient (Muller et al., 2016b). The 
neurologists conducted remote visits via a Cisco EX60 unit from the 
examination room where also the traditional face‐to‐face consulta‐
tions took place. Two neurologists (KIM and SIB) carried out all con‐
sultations without neurological examinations, which was initiated by 
check of inclusion criteria and completion of diagnostic classification.
Norwegian‐speaking males and females aged 16–65 years re‐
ferred to the Department of Neurology from primary care for man‐
agement of MOH with maximum 4 months waiting time to reduce the 
risk of exclusions by time limitation and to adapt to the Department's 
waiting list, were accepted for inclusion. All patients had chronic 
headache	 (headache	≥15	days	per	month	 for	more	 than	3	months)	
and at least one primary headache disorder classified by one of the 
study investigators (KIM and SIB; ICHD, 2004). All fulfilled the re‐
vised	criteria	of	MOH	classification	(use	of	simple	analgesics	≥15	days	
per month or acute medication, triptans, ergots, opioids or combina‐
tion	analgesics	≥10	days	per	month	for	over	3	months;	Olesen	et	al.,	
2006). Those with abnormal findings on either clinical neurological 
examination reported by the referring doctor or by brain imaging sug‐
gestive of secondary etiology and being examined by a specialist for 
headache within 2 years prior to inclusion time were excluded to en‐
sure that only naïve patients with new onset headache were included.
2.2 | Outcome variables
Data were collected at baseline (consultations by KIM and SIB) 
and at 3 and 12 months (questionnaires) with a reminder after 
2 weeks to the nonresponders. We sent a structured question‐





ache characteristics including diagnostic classification according 
to International Classification of Headache Disorders‐2 ++(ICHD, 
2004) of the participants were recorded. The patients responded 
to “number of headache days per month for the last three months” 
to classify chronic headache. Use of painkillers (OTC and pre‐
scriptive) and use of triptans were ticked off on the registration 
form. Treatment options and advices recommended by the spe‐
cialist were evidence based (Evers & Jensen, 2011), and supplied 
by general advices as followed: Withdrawal of medication, reduc‐
tion in use of medication (misuse of eg, triptans, patient denying 
complete withdrawal), preventive treatment, triptan use, physical 
training, trigger avoidance, regular sleep, weight reduction, men‐
struation advises (use of long‐lasting triptans before and during 
menstruation periods, consulting primary physician to regulate or 
postpone menstruation cycles if suitable).
All patients were brain scanned, either by CT (spiral technique 
with reconstructions in coronal, sagittal, and axial planes) or by 1.5T 
MRI machines with a Head/SENSE‐Head/Flex‐L coil. All MRI images 
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were presented with sagittal 3D fluid‐attenuated inversion recovery, 
axial T2 turbo spin echo 4 mm, axial T2 fast field echo 4 mm, axial 
diffusion 4 mm, and sagittal T1 spin echo 5.5 mm. Experienced ra‐
diologists or neuroradiologists evaluated the images. Neuroimaging 
findings were classified as “normal,” “nonsignificant,” or “significant” 
(Sempere et al., 2005).
2.3 | Statistical analyses
We used SPSS 23 for data analyses. Gaussian distribution of con‐
tinuous variables was confirmed by inspection of histograms and 
by calculating kurtosis and skewness. Descriptive variables are pre‐
sented as mean (SD) or numbers (%). Categorical variables were com‐
pared by chi‐square test and continuous data by two‐sided Student 
t test with p < 0.05 as level of significance. Comparisons between 
variables with small numbers are labeled “not applicable” (NA). We 
used mixed between‐within participants ANOVA to assess whether 
change in HIT‐6 and VAS differed between telemedicine and tra‐
ditional consultations prospectively over three time points. These 
results are shown in figures and presented with F scores and sig‐
nificance levels. Details about power estimation are published else‐
where (Muller et al., 2016a).
2.4 | Consent, registration and ethics
Oral and written consent were obtained from all participants before 
data collection. The Norwegian National Committee for Medical and 
Health Research Ethics (REC), number 2009/1430/REK approved 
F I G U R E  1   Flowdiagram of participants throughout the study
Screened consecutively for eligibility 
(n=557)
Not included (n=148)
♦ Did not meet inclusion criteria (n=58)
♦ Declined participation (n=57)
♦ Declined consultation (n=20)










3 months after consultation
Responders (n=47) Responders (n=39)
12 months after consultation
Responders (n=39) Responders (n=37)
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the study. The trial was registered at the Norwegian Research and 
Management database (ID3897/HST959‐10) and at ClinicalTrials.
gov (id. NCT02270177).
3  | RESULTS
From a total population of 557 headache patients referred to spe‐
cialist for second opinion, 102 classified as MOH (18.3%) fulfilled the 
inclusion criteria and were included and randomized to either video 
consultations (n = 51) or traditional consultations (n = 51; Figure 1). 
At 3‐month follow‐up, 47/51 (92.2%) in the video group and 39/51 
(76.5%) in the traditional group responded (p = 0.054), giving a total 
response rate of 86/102 (84.3%). The equivalent responses at 1‐year 
follow‐up were 39/51 (76.5%) in the video group, 37/51 (72.5%) in 
the traditional group (p = 0.67), and 76/102 (74.5%) overall. Table 1 
shows social and demographic data in comparison between patient 
groups consulted by video and traditionally. No statistically signifi‐
cant differences between the groups were found. Also, waiting time 
to specialist and consultation time were similar, and there was no 
significant change in frequency of sick leave from baseline to 1 year 
(Table 1).
Most common primary headaches classified in the participants 
and uses of medications are presented in Table 2. All patients had 
normal MRI or CT of the brain before the consultation (Table 2). 
Use of painkillers was only minimally reduced at 1‐year follow‐up 
compared to baseline, while triptan use had increased slightly 
(Table 2). Treatment and specific advices are listed in Table 2. In 
the video group, withdrawal or reduction of medication use were 
recommended in 47 (92.1%) compared to 45 (88.3%) in the others, 
p = 0.58.
Table 3 shows endpoint variables in the two groups at baseline, 
3 months and 12 months. Mean HIT‐6 was reduced by 6.3 (9.5%) 
in the video group and 7.4 (11.2%) in the traditional group from 
baseline	to	12	months	(95%	CI	−2.3	to	6.5,	p = 0.44). In any group, 
frequency of patients with <15 headache days per month in the 
follow‐up period varied between 21.3% and 27.0% (Table 3). VAS 
improved 2.3 points (31.5%) at average (video group) and 2.4 (tradi‐
tional	group;	33.3%)	in	the	same	period	(95%	CI	−1.2	to	1.2,	p = 0.76). 
All comparisons are insignificant (Table 3). Likewise, about 40% in 
both groups reported <15 headache days per month during the last 
3 months at 3‐month follow‐up while the frequency of patients with 
episodic headache at 1‐year follow‐up was reduced to 26.6% (video 
group) and 32.4% (traditional group; Table 3). Pooled data showed an 
episodic headache pattern in 41.9% at 3 months and 28.9% at 1 year.
Estimation of reliability, HIT‐6 Cronbach alpha coefficients were 
0.82, 0.79, and 0.78 at baseline, 3 month and 1 year, respectively. 
Mixed between‐within participants ANOVA analysis showed no sig‐
nificant differences in HIT‐6 or VAS between the video group and 
the traditional group measured prospectively at three time points, 
F(2, 62) = 0.381, p = 0.54 and F(1, 56) = 0.117, p = 0.73 for HIT‐6 and 
VAS, respectively (Figures 2 and 3).
TA B L E  1   Headache characteristics at baseline and at 1‐year follow‐up in randomized groups of patients with medication overuse 
headache referred to specialist for second opinion
 
Baseline 1‐year follow‐up
Video (n = 51) Traditional (n = 51) p value Video (n = 39) Traditional (n = 37) p value
Age (years) 40.5 (11.7) 39.1 (13.8) 0.56 40.6 (11.5) 37.7 (14.4) 0.33
Females 38 (74.5) 39 (76.5) 1.0 29 (74.4) 30 (81.1) 0.59
Age at headache onset 
(years)
23.3 (14.7) 23.0 (12.9) 0.93 22.2 (15.3) 23.2 (13.9) 0.78
Headache duration (year) 18.0 (13.4) 16.5 (13.3) 0.56 19.6 (14.0) 15.4 (13.4) 0.18
Consultation time 
(minutes)
44.3 (8.0) 46.9 (11.3) 0.19    
Primary headaches       
Migraine 50 (98.0) 48 (94.1) 0.62 38 (97.4) 34 (92.0) 0.35
Tension type headache 40 (78.4) 41 (80.4) 1.0 31 (78.5) 30 (81.1) 1.0
Normal MRI 39 33 1.0    
Normal CT 12 18 0.46    
Painkillers 
(over‐the‐counter)
46 (90.2) 48 (94.1) 0.72 33 (84.6) 34 (91.9) 0.48
Painkillers (prescription) 16 (31.4) 14 (27.5) 0.83 11 (28.2) 8 (21.6) 0.60
Painkillers daily 20 (39.2) 18 (35.3) 0.28 14 (35.9) 9 (24.3) 0.15
Triptans 22 (43.1) 26 (51.0) 0.87 20 (51.3) 21 (56.7) 0.75
Triptans daily 4 (7.8) 1 (2.0) NA 1 (2.6) 0 NA
Note: Data are presented as mean (SD) or numbers (%).
Abbreviation: NA, not applicable.
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4  | DISCUSSION
The results from this RCT trial document that video consultations 
are noninferior to traditional face‐to‐face consultations in treating 
MOH. The condition improved until 3 months, then deteriorated 
slightly at 1‐year examination in both groups. At 1‐year assessment, 
HIT‐6 improved by approximately 10% and VAS about 30% com‐
pared to baseline in both groups. After 3 months, 40%/43% (video/
traditional groups), respectively 27%/32% at 1‐year observation had 
an episodic pattern of headache. Use of video consultations is there‐
fore a good alternative in consulting patients with MOH.
Treatment strategies for MOH are largely based on experience 
and consensus (Evers & Jensen, 2011), and scientific evidence exists 
only to a limited extent (Chiang, Schwedt, Wang, & Dodick, 2016). 
Neither is it reported similar studies like the present one investi‐
gating the efficacy of using electronic devices in consulting MOH 
patients despite the existence of guidelines for teleheadache consul‐
tations (Wechsler et al., 2013). Beyond stroke, there are only a few 
randomized controlled telemedicine trials in neurological conditions 
in general (Chua, Craig, Wootton, & Patterson, 2001; Rubin, Wellik, 
Channer, & Demaerschalk, 2013), and headache in particular (Muller 
et al., 2016a). Thus, telemedicine is widely used in neurological clin‐
ics as well as for headache management (Davis, Coleman, Harnar, & 
King, 2014; George et al., 2012; Yurkiewicz et al., 2012).
In a previous study where new neurological patients (including 
headache) were randomized to either telemedicine or face‐to‐face 
consultations in an outpatient specialist center, feasibility, patient' 
satisfaction, and number of drug prescriptions were similar in both 
groups (Chua et al., 2001). In contrast, patients in the telemedicine 
group had more investigations and were more concerned about 
confidentiality and embarrassment (Chua et al., 2001). A Cochrane 
report reviewing 93 eligible telemedicine trials until June 2013 with 
a wide range of conditions (other than neurological) concluded that 
cost and acceptability by patients and healthcare are uncertain 
due to limited data available (Flodgren, Rachas, Farmer, Inzitari, & 
Shepperd, 2015). Disease severity and purpose of the intervention 
(eg, monitoring chronic diseases, diagnose new patients) are some 
factors that may influence the outcome (Flodgren et al., 2015). 
Recently, it is shown that video consultations for new patients with 
TA B L E  2   Treatment and advices to patients with medication 





(n = 51) p value
Reduction of acute 
medication
30 (58.8) 26 (51.0) 0.55
Withdrawal of acute 
medication
17 (33.3) 19 (37.3) 0.84
Preventive treatment* 40 (78.4) 33 (64.7) 0.19
Antihypertensives 12 (23.5) 13 (25.5) 1.0
Antiepileptics 10 (19.6) 10 (19.6) 1.0
Antidepressants 20 (39.2) 12 (23.5) 0.14
Triptans 13 (25.5) 12 (23.5) 1.0
Physical training 19 (37.3) 21 (41.2) 1.0
Trigger avoidance 11 (21.6) 20 (39.2) 0.08
Regular sleep 2 (3.9) 9 (17.6) NA
Weight reduction 1 (2.0) 0 NA
Menstruation advices 1 (2.0) 0 NA
Note: Some patients received more than one drug, numbers (%).
Abbreviation: NA, not applicable.
*Indicates any preventive drug.
TA B L E  3   Endpoint variables at 3 months and at 1‐year follow‐up in randomized groups of patients with medication overuse headache 
referred to specialist for second opinion
 












(n = 37) p valuea
HIT‐6 66.3 (4.7) 65.8 (3.7) 0.56 58.7 (9.0) 61.5 (6.8) 0.12 60.0 (9.1) 58.4 (8.3) 0.44
∆HIT‐6    7.4 (10.3) 4.8 (8.0) 0.21 6.6 (11.2) 7.8 (8.7) 0.63
<15 headache 0 0  10 (21.3) 10 (25.6) 0.80 9 (23.1) 10 (27.0) 0.60
Days per month
<7 headache 0 4  0 3  0 2  
Days per month
HIT‐6	reduction	≥5    29 (61.7) 15 (38.5) 0.051 11 (21.6) 11 (29.7) 0.80
HIT‐6	increase	≥5    7 (15.0) 3 (7.7) 0.34 6 (11.8) 2 (3.9) 0.27
VAS 7.3 (2.0) 7.2 (2.4) 0.86 4.3 (2.9) 4.9 (2.2) 0.29 5.0 (2.6) 4.8 (2.5) 0.76
∆VAS    3.0 (3.3) 2.3 (3.2) 0.32 2.4 (3.2) 2.5 (3.8) 0.95
Episodic headache 0 0  19 (40.4) 17 (43.6) 0.80 10 (26.6) 12 (32.4) 0.54
Note: Data are presented as mean (SD) or numbers (%)
Abbreviations: HIT‐6, Headache impact test; VAS, Visual analogue scale.
aCompared to baseline. 
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primary, nonacute headaches referred from general practice to spe‐
cialist are cost saving, feasible, satisfying for the patients, effective 
and safe in a mixed rural and urban population (Muller et al., 2016b; 
Muller, Alstadhaug, & Bekkelund, 2017a, 2017b). In line with this, the 
present secondary analyses of the MOH subgroup shows that after 
12 months monitoring of treatment effect, neither headache burden 
nor pain level were statistically in favor of traditional consultations 
(Figures 2 and 3). Consequently, patients with difficult headache 
may benefit from use of information and communication technolo‐
gies in consultation with headache specialists, and should therefore 
undergo further investigations.
Methodologically controversies associated with MOH make 
comparisons with others difficult. Changes in definition over time 
and invalid classification of the preexisting primary headache dis‐
order(s) may contribute to data uncertainty (Ferrari, Coccia, & 
Sternieri, 2008). In a previous Norwegian study, headache days was 
reduced by 32% and medication days by 46% in a group random‐
ized to brief intervention (BI; advices and education) compared to 
the control group treated by “standard of care” in general practice 
(Kristoffersen et al., 2015). Headache specialists gave BI as a 1‐
day course. This study demonstrates the importance of a system‐
atic approach in the treatment of MOH. In the present study, we 
F I G U R E  2   Comparisons of HIT‐6 
over three time points between 
headache patients randomized to 
video consultations and traditional 
consultations. There were no differences 
between the groups (mixed design 
ANOVA; F(2, 62) = 0.381, p = 0.54)
F I G U R E  3   Comparisons of visual 
analogue scale (VAS) over three time 
points between headache patients 
randomized to video consultations and 
traditional consultations. There were no 
differences between the groups (mixed 
design ANOVA; F(1, 56) = 0.117, p = 0.73) 
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administered advices by a structured interview that included dis‐
continuation of overused medicine and supplementary preventive 
medication to the migraineurs as recommended (Chiang et al., 2016). 
The results are within range of a clinically important difference for 
HIT‐6 and VAS (Coeytaux, Kaufman, Chao, Mann, & Devellis, 2006; 
Hawker, Mian, Kendzerska, & French, 2011). In a multicenter study, 
46% reversed to episodic headache 6 months after intervention 
(Tassorelli, Jensen, et al., 2014). Previous studies report a 1‐year 
relapse rate of 40% (Katsarava et al., 2005). Despite differences 
in definition, primary endpoints, and the fact that trials comparing 
treatment options in MOH are largely performed in tertiary centers, 
our results are comparable (Katsarava, Limmroth, Finke, Diener, & 
Fritsche, 2003).
Continuously enrollment of patients referred to specialist for 
second opinion within a defined geographical area where all special‐
ists are centralized into one hospital, strengthen the generalizability 
of the sample and minimizes dropouts by providing full control over 
patient's logistics. Another favorable aspect is the optimal balance 
between the groups in the trial as far as size and background vari‐
ables concerns, which was created by the randomization procedure. 
Contrary, the secondary research setting increases the risk of statis‐
tical type 2 failures due to underpowered sample size. Furthermore, 
the common location at the hospital where all the consultations took 
place may have biased the results. Another uncertainty is lack of in‐
formation about reason(s) why withdrawal or reduction of medica‐
tion was not recommended in 9%. This is discussed more detailed 
elsewhere (Muller, Alstadhaug, & Bekkelund, 2017b).
5  | CONCLUSIONS
The pattern of treatment responses and long‐term treatment out‐
come after one‐time consultation for patients with MOH were 
similar in both groups providing evidence that video consultations 
are noninferior compared to traditional consultations in treating 
these patients. Consulting MOH patients by using video devices 
is an option to consider in suitable areas. The high frequency of 
MOH among patients referred from general practice to specialist, 
demonstrates a need for easy access to second opinion for this 
patient group.
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